SGLT2 Inhibitors and UTI: When to Stop
SGLT2 inhibitors should generally NOT be routinely stopped during a simple urinary tract infection 1, 2. The evidence shows these medications do not significantly increase UTI risk and can be safely continued in most cases, even in patients with recent UTI history 3.
The Evidence on SGLT2i and UTI Risk
What the Guidelines Say
The most authoritative guidance comes from the 2022 KDIGO consensus, which recommends withholding SGLT2 inhibitors only during periods of prolonged fasting, surgery, or critical medical illness when patients may be at greater risk for ketosis 1. Notably, UTI is not listed as a reason to discontinue therapy.
The mechanism of concern is straightforward: SGLT2 inhibitors cause glucosuria (glucose in urine), which theoretically creates a favorable environment for bacterial and fungal growth. However, large randomized trials demonstrate that SGLT2 inhibitors do not increase the risk of urinary tract infections 4, 5.
Real-World Evidence
A 2025 study of patients with type 2 diabetes who developed UTI found that initiating SGLT2 inhibitors within 3 months after UTI was associated with lower mortality (HR 0.59), reduced kidney complications, and fewer infection-related outcomes compared to DPP-4 inhibitors 3
Analysis of the CANVAS and CREDENCE trials involving 8,614 participants showed canagliflozin did not increase the risk of first UTI (HR 1.06) or total UTI events (HR 1.01) 5
Even in patients with abnormal urine dipstick findings (leukocyte esterase or nitrites), SGLT2 inhibitors did not further increase UTI risk 5
When SGLT2i Should Be Temporarily Withheld
The primary concern is NOT the UTI itself, but rather the risk of euglycemic ketoacidosis during acute illness. The 2022 KDIGO guidelines specify 1:
- Prolonged fasting
- Surgery or perioperative periods (withhold at least 2 days before procedures requiring hospitalization)
- Critical medical illness (sepsis, severe dehydration, hemodynamic instability)
Specific Clinical Scenarios Requiring Caution
Consider temporary discontinuation if:
Patient has pyelonephritis with systemic symptoms (fever, hemodynamic instability, severe nausea/vomiting preventing oral intake) - this represents acute illness, not the infection per se 6
Volume depletion from vomiting/diarrhea accompanying UTI - SGLT2i cause osmotic diuresis that can worsen hypovolemia and precipitate AKI 6
Patient requires bowel preparation or prolonged NPO status 1
Signs of ketoacidosis (nausea, vomiting, abdominal pain, dyspnea) - check blood ketones 7, 6
The Genital Infection Distinction
It's critical to distinguish UTI from genital mycotic infections (GMI). While SGLT2 inhibitors clearly increase GMI risk (6% vs 1% with placebo), these are typically mild, easily treated with topical antifungals, and do not require drug discontinuation 7, 4.
The rare exception is Fournier's gangrene (necrotizing fasciitis of the perineum), which requires immediate SGLT2i discontinuation and surgical intervention 7, 4.
Practical Algorithm for UTI Management
For uncomplicated cystitis:
- Continue SGLT2 inhibitor
- Treat UTI with appropriate antibiotics
- Ensure adequate hydration
- Monitor for resolution
For complicated UTI or pyelonephritis:
- Assess volume status and ability to maintain oral intake
- If patient is euvolemic and tolerating oral fluids → continue SGLT2i
- If patient has nausea/vomiting, poor oral intake, or volume depletion → temporarily withhold SGLT2i until acute illness resolves
- Check blood or urine ketones if symptoms suggest ketoacidosis
- Resume SGLT2i once patient is eating/drinking normally and acute illness has resolved
Common Pitfalls to Avoid
Don't reflexively stop SGLT2 inhibitors for simple UTI - this deprives patients of significant cardiovascular and renal protection 3. The evidence shows these medications are safe to continue and may even improve long-term outcomes post-infection.
Don't confuse genital mycotic infections with UTI - GMI are more common but rarely serious and don't require drug discontinuation 7, 6.
Don't restart too quickly after severe illness - ensure patient is eating and drinking normally before resuming 1.
Risk Factors Requiring Enhanced Monitoring
While not contraindications, these factors warrant closer surveillance 6:
- Uncontrolled hyperglycemia
- Older adults
- Prior history of recurrent genitourinary infections
- Uncircumcised males
- Concurrent diuretic use
Bottom Line
The decision to stop SGLT2 inhibitors should be based on the severity of systemic illness and metabolic stability, not the presence of UTI itself. Simple cystitis does not require discontinuation. Temporary withholding is appropriate for severe pyelonephritis with systemic symptoms, primarily to mitigate ketoacidosis risk during acute metabolic stress, not because of infection-specific concerns 1, 2.